Mitochondrial DNA replacement techniques to prevent human mitochondrial diseases

Background: Mitochondrial DNA (mtDNA) diseases are a group of maternally inherited genetic disorders caused by a lack of energy production. Currently, mtDNA diseases have a poor prognosis and no known cure. The chance to have unaffected offspring with a genetic link is important for the affected families, and mitochondrial replacement techniques (MRTs) allow them to do so. MRTs consist of transferring the nuclear DNA from an oocyte with pathogenic mtDNA to an enucleated donor oocyte without pathogenic mtDNA. This paper aims to determine the efficacy, associated risks, and main ethical and legal issues related to MRTs. Methods: A bibliographic review was performed on the MEDLINE and Web of Science databases, along with searches for related clinical trials and news. Results: A total of 48 publications were included for review. Five MRT procedures were identified and their efficacy was compared. Three main risks associated with MRTs were discussed, and the ethical views and legal position of MRTs were reviewed. Conclusions: MRTs are an effective approach to minimizing the risk of transmitting mtDNA diseases, but they do not remove it entirely. Global legal regulation of MRTs is required

Multicompartmental Lipopolyplex as vehicle for antigens and genes delivery in vaccine formulations

Vector design and its characterization is an area of great interest in current vaccine research. In this article, we have formulated and characterized a multicompartmental lipopolyplex, which associates multiple liposomes and polyplexes in the same complex. These particles allow the simultaneous delivery of lipid or water-soluble antigens associated with genes to the same cell, in much higher amounts than conventional lipopolyplexes. The vector characterization and optimization were carried out using liposomes with entrapped carboxyfluorescein and adapted electrophoretic assays. Two types of lipopolyplexes (containing hydrophilic or lipophilic antigens) were employed to evaluate their interest in vaccination. The lipopolyplex loaded with an extract of water-soluble melanoma proteins proved to efficiently induce humoral response in murine melanoma model, increasing the levels of IgM and IgG. The specificity of the immune response induced by the lipopolyplex was demonstrated in mice with the lipopolyplex containing the GD3 ganglioside lipid antigen, abundant in melanoma cells. The levels of anti-GD3 IgG increased markedly without modifying the expression of humoral antibodies against other gangliosides

Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

The antitumor response after therapeutic vaccination has a limited effect and seems to be related to the presence of T regulatory cells (Treg), which express the immunoregulatory molecules CTLA4 and Foxp3. The blockage of CTLA4 using antibodies has shown an effective antitumor response conducing to the approval of the human anti-CTLA4 antibody ipilimumab by the US Food and Drug Administration. On the other hand, Foxp3 is crucial for Treg development. For this reason, it is an attractive target for cancer treatment. This study aims to evaluate whether combining therapeutic vaccination with CTLA4 or Foxp3 gene silencing enhances the antitumor response. First, the "in vitro" cell entrance and gene silencing efficacy of two tools, 2'-O-methyl phosphorotioate-modified oligonucleotides (2'-OMe-PS-ASOs) and polypurine reverse Hoogsteen hairpins (PPRHs), were evaluated in EL4 cells and cultured primary lymphocytes. Following B16 tumor transplant, C57BL6 mice were vaccinated with irradiated B16 tumor cells engineered to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) and were intraperitoneally treated with CTLA4 and Foxp3 2'-OMe-PS-ASO before and after vaccination. Tumor growth, mice survival, and CTLA4 and Foxp3 expression in blood cells were measured. The following results were obtained: 1) only 2'-OMe-PS-ASO reached gene silencing efficacy "in vitro"; 2) an improved survival effect was achieved combining both therapeutic vaccine and Foxp3 antisense or CTLA4 antisense oligonucleotides (50% and 20%, respectively); 3) The blood CD4+CD25+Foxp3+ (Treg) and CD4+CTLA4+ cell counts were higher in mice that developed tumor on the day of sacrifice. Our data showed that tumor cell vaccine combined with Foxp3 or CTLA4 gene silencing can increase the efficacy of therapeutic antitumor vaccination

Liver Gene Therapy: Employing Surgery and Radiology for Translational Research

Gene therapy is a therapeutic strategy that aims to employ nucleic acids as drugs for the transient or permanent treatment of inherited or acquired pathologies. Based on the type of vector employed for the gene transfer, gene therapy can be classified as viral gene therapy and nonviral gene therapy. Nonviral gene therapy is less efficient but safer than viral gene therapy. Hydrodynamic naked DNA transfer has shown great translational potential, achieving therapeutic levels of a human protein in the murine model. The translational process of the procedure has already been performed. Different radiologic and surgical approaches permitted pressurizing the liver in vivo by excluding its vascularization partially or totally. These approaches mediated a tissue rate of human alpha-1-antitrypsin protein translation (100–1000 copies per cell) close to those obtained with the mouse gold standard model in a safe mode that could be translated to human settings

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed

Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic

Our aim in this chapter is to present the state of the art, including our own group research, in the field of immunosuppressant pharmacogenetics in the four main types of solid organ transplantation: kidney, heart, lung, and liver. The main focus will be on those findings in the field that have been widely investigated and then in those that are close to clinical implementation, mainly CYP3A5 genotyping for the adjustment of the initial tacrolimus dose. This recommendation will be discussed in more detail, explaining its clinical potential as well as its limitations. To end, a short opinion about the feasibility of implementation in the health systems as well as discussion about private companies selling pharmacogenetic tests will be presented

Gold Nanoparticle-Assisted Virus Formation by Means of the Delivery of an Oncolytic Adenovirus Genome

[EN] Oncolytic adenoviruses are a therapeutic alternative to treat cancer based on their ability to replicate selectively in tumor cells. However, their use is limited mainly by the neutralizing antibody (Nab) immune response that prevents repeated dosing. An alternative to facilitate the DNA access to the tumor even in the presence of anti-viral Nabs could be gold nanoparticles able to transfer DNA molecules. However, the ability of these nanoparticles to carry large DNA molecules, such as an oncolytic adenovirus genome, has not been studied. In this work, gold nanoparticles were functionalized with different amounts of polyethylenimine to transfer in a safe and efficient manner a large oncolytic virus genome. Their transfer efficacy and final effect of the oncolytic virus in cancer cells are studied. For each synthesized nanoparticle, (a) DNA loading capacity, (b) complex size, (c) DNA protection ability, (d) transfection efficacy and (e) cytotoxic effect were studied. We observed that small gold nanoparticles (70-80 nm in diameter) protected DNA against nucleases and were able to transfect the ICOVIR-15 oncolytic virus genome encoded in pLR1 plasmid. In the present work, efficient transgene RNA expression, luciferase activity and viral cytopathic effect on cancer cells are reported. These results suggest gold nanoparticles to be an efficient and safe vector for oncolytic adenovirus genome transfer.This research was supported by University of Valencia 'Ayuda a la Investigacion', Asociacion Pablo Ugarte and European Regional Development Fund (VLC-CAMPUS).Sendra, L.; Miguel, A.; Navarro-Plaza, MC.; Herrero, MJ.; De La Higuera, J.; Cháfer-Pericás, C.; Aznar, E.... (2020). Gold Nanoparticle-Assisted Virus Formation by Means of the Delivery of an Oncolytic Adenovirus Genome. Nanomaterials. 10(6):1-16. https://doi.org/10.3390/nano10061183S116106Cebrián, V., Martín-Saavedra, F., Yagüe, C., Arruebo, M., Santamaría, J., & Vilaboa, N. (2011). Size-dependent transfection efficiency of PEI-coated gold nanoparticles. Acta Biomaterialia, 7(10), 3645-3655. doi:10.1016/j.actbio.2011.06.018Shukla, R., Bansal, V., Chaudhary, M., Basu, A., Bhonde, R. R., & Sastry, M. (2005). Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the Cellular Compartment: A Microscopic Overview. Langmuir, 21(23), 10644-10654. doi:10.1021/la0513712Niidome, T., Nakashima, K., Takahashi, H., & Niidome, Y. (2004). Preparation of primary amine-modified gold nanoparticles and their transfection ability into cultivated cellsElectronic Supplementary Information (ESI) available: A TEM image of the complex at a w/w ratio of 11. See http://www.rsc.org/suppdata/cc/b4/b406189f/. Chemical Communications, (17), 1978. doi:10.1039/b406189fSandhu, K. K., McIntosh, C. M., Simard, J. M., Smith, S. W., & Rotello, V. M. (2001). Gold Nanoparticle-Mediated Transfection of Mammalian Cells. Bioconjugate Chemistry, 13(1), 3-6. doi:10.1021/bc015545cThomas, M., & Klibanov, A. M. (2003). Conjugation to gold nanoparticles enhances polyethylenimine’s transfer of plasmid DNA into mammalian cells. Proceedings of the National Academy of Sciences, 100(16), 9138-9143. doi:10.1073/pnas.1233634100Noh, S. M., Kim, W.-K., Kim, S. J., Kim, J. M., Baek, K.-H., & Oh, Y.-K. (2007). Enhanced cellular delivery and transfection efficiency of plasmid DNA using positively charged biocompatible colloidal gold nanoparticles. Biochimica et Biophysica Acta (BBA) - General Subjects, 1770(5), 747-752. doi:10.1016/j.bbagen.2007.01.012Chan, T. G., Morse, S. V., Copping, M. J., Choi, J. J., & Vilar, R. (2018). Targeted Delivery of DNA-Au Nanoparticles across the Blood-Brain Barrier Using Focused Ultrasound. ChemMedChem, 13(13), 1311-1314. doi:10.1002/cmdc.201800262Mbatha, L. S., & Singh, M. (2019). Starburst Poly(amidoamine) Dendrimer Grafted Gold Nanoparticles as a Scaffold for Folic Acid-Targeted Plasmid DNA Delivery In Vitro. Journal of Nanoscience and Nanotechnology, 19(4), 1959-1970. doi:10.1166/jnn.2019.15798Cobley, C. M., Chen, J., Cho, E. C., Wang, L. V., & Xia, Y. (2011). Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem. Soc. Rev., 40(1), 44-56. doi:10.1039/b821763gCho, E. C., Au, L., Zhang, Q., & Xia, Y. (2010). The Effects of Size, Shape, and Surface Functional Group of Gold Nanostructures on Their Adsorption and Internalization by Cells. Small, 6(4), 517-522. doi:10.1002/smll.200901622Pissuwan, D., Niidome, T., & Cortie, M. B. (2011). The forthcoming applications of gold nanoparticles in drug and gene delivery systems. Journal of Controlled Release, 149(1), 65-71. doi:10.1016/j.jconrel.2009.12.006Rosi, N. L., Giljohann, D. A., Thaxton, C. S., Lytton-Jean, A. K. R., Han, M. S., & Mirkin, C. A. (2006). Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation. Science, 312(5776), 1027-1030. doi:10.1126/science.1125559Ghosh, P. S., Kim, C.-K., Han, G., Forbes, N. S., & Rotello, V. M. (2008). Efficient Gene Delivery Vectors by Tuning the Surface Charge Density of Amino Acid-Functionalized Gold Nanoparticles. ACS Nano, 2(11), 2213-2218. doi:10.1021/nn800507tMassich, M. D., Giljohann, D. A., Seferos, D. S., Ludlow, L. E., Horvath, C. M., & Mirkin, C. A. (2009). Regulating Immune Response Using Polyvalent Nucleic Acid−Gold Nanoparticle Conjugates. Molecular Pharmaceutics, 6(6), 1934-1940. doi:10.1021/mp900172mRyou, S.-M., Kim, S., Jang, H. H., Kim, J.-H., Yeom, J.-H., Eom, M. S., … Lee, K. (2010). Delivery of shRNA using gold nanoparticle–DNA oligonucleotide conjugates as a universal carrier. Biochemical and Biophysical Research Communications, 398(3), 542-546. doi:10.1016/j.bbrc.2010.06.115Stobiecka, M., & Hepel, M. (2011). Double-shell gold nanoparticle-based DNA-carriers with poly-l-lysine binding surface. Biomaterials, 32(12), 3312-3321. doi:10.1016/j.biomaterials.2010.12.064Sharma, A., Tandon, A., Tovey, J. C. K., Gupta, R., Robertson, J. D., Fortune, J. A., … Mohan, R. R. (2011). Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine: Nanotechnology, Biology and Medicine, 7(4), 505-513. doi:10.1016/j.nano.2011.01.006Yan, X., Blacklock, J., Li, J., & Möhwald, H. (2011). One-Pot Synthesis of Polypeptide–Gold Nanoconjugates for in Vitro Gene Transfection. ACS Nano, 6(1), 111-117. doi:10.1021/nn202939sShan, Y., Luo, T., Peng, C., Sheng, R., Cao, A., Cao, X., … Shi, X. (2012). Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials, 33(10), 3025-3035. doi:10.1016/j.biomaterials.2011.12.045Trigueros, Domènech, Toulis, & Marfany. (2019). In Vitro Gene Delivery in Retinal Pigment Epithelium Cells by Plasmid DNA-Wrapped Gold Nanoparticles. Genes, 10(4), 289. doi:10.3390/genes10040289Munsell, E. V., Fang, B., & Sullivan, M. O. (2018). Histone-Mimetic Gold Nanoparticles as Versatile Scaffolds for Gene Transfer and Chromatin Analysis. Bioconjugate Chemistry, 29(11), 3691-3704. doi:10.1021/acs.bioconjchem.8b00611Dhanya, G. R., Caroline, D. S., Rekha, M. R., & Sreenivasan, K. (2018). Histidine and arginine conjugated starch-PEI and its corresponding gold nanoparticles for gene delivery. International Journal of Biological Macromolecules, 120, 999-1008. doi:10.1016/j.ijbiomac.2018.08.142Hersey, P., & Gallagher, S. (2013). Intralesional immunotherapy for melanoma. Journal of Surgical Oncology, 109(4), 320-326. doi:10.1002/jso.23494Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., … Lattime, E. C. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Therapy, 6(5), 409-422. doi:10.1038/sj.cgt.7700066Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., … Nemunaitis, J. J. (2009). Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. Journal of Clinical Oncology, 27(34), 5763-5771. doi:10.1200/jco.2009.24.3675Goins, W. F., Huang, S., Cohen, J. B., & Glorioso, J. C. (2014). Engineering HSV-1 Vectors for Gene Therapy. Herpes Simplex Virus, 63-79. doi:10.1007/978-1-4939-0428-0_5Dummer, R., Rochlitz, C., Velu, T., Acres, B., Limacher, J.-M., Bleuzen, P., … Urosevic, M. (2008). Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma. Molecular Therapy, 16(5), 985-994. doi:10.1038/mt.2008.32GUPTA, P., SU, Z., LEBEDEVA, I., SARKAR, D., SAUANE, M., EMDAD, L., … DENT, P. (2006). mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacology & Therapeutics, 111(3), 596-628. doi:10.1016/j.pharmthera.2005.11.005Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., … Barouch, D. H. (2007). Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. Journal of Virology, 81(9), 4654-4663. doi:10.1128/jvi.02696-06Mast, T. C., Kierstead, L., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., … Shiver, J. W. (2010). International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine, 28(4), 950-957. doi:10.1016/j.vaccine.2009.10.145Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., … Goudsmit, J. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine, 29(32), 5203-5209. doi:10.1016/j.vaccine.2011.05.025Na, Y., Nam, J.-P., Hong, J., Oh, E., Shin, H. C., Kim, H. S., … Yun, C.-O. (2019). Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration. Journal of Controlled Release, 305, 75-88. doi:10.1016/j.jconrel.2019.04.040Kasala, D., Yoon, A.-R., Hong, J., Kim, S. W., & Yun, C.-O. (2016). Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy. Nanomedicine, 11(13), 1689-1713. doi:10.2217/nnm-2016-0060Kwon, O.-J., Kang, E., Kim, S., & Yun, C.-O. (2011). Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. Journal of Controlled Release, 155(2), 317-325. doi:10.1016/j.jconrel.2011.06.014YOSHIHARA, C., HAMADA, K., KURODA, M., & KOYAMA, Y. (2011). Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy. Oncology Letters, 3(2), 387-390. doi:10.3892/ol.2011.467Rojas, J. J., Guedan, S., Searle, P. F., Martinez-Quintanilla, J., Gil-Hoyos, R., Alcayaga-Miranda, F., … Alemany, R. (2010). Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses. Molecular Therapy, 18(11), 1960-1971. doi:10.1038/mt.2010.173Rincón, E., Cejalvo, T., Kanojia, D., Alfranca, A., Rodríguez-Milla, M. Á., Hoyos, R. A. G., … García-Castro, J. (2017). Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget, 8(28), 45415-45431. doi:10.18632/oncotarget.17557Carette, J. E., Graat, H. C. A., Schagen, F. H. E., Abou El Hassan, M. A. I., Gerritsen, W. R., & van Beusechem, V. W. (2005). Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. The Journal of Gene Medicine, 7(8), 1053-1062. doi:10.1002/jgm.754Stanton, R. J., McSharry, B. P., Armstrong, M., Tomasec, P., & Wilkinson, G. W. G. (2008). Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. BioTechniques, 45(6), 659-668. doi:10.2144/000112993Bayo-Puxan, N., Cascallo, M., Gros, A., Huch, M., Fillat, C., & Alemany, R. (2006). Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. Journal of General Virology, 87(9), 2487-2495. doi:10.1099/vir.0.81889-0Brust, M., Fink, J., Bethell, D., Schiffrin, D. J., & Kiely, C. (1995). Synthesis and reactions of functionalised gold nanoparticles. Journal of the Chemical Society, Chemical Communications, (16), 1655. doi:10.1039/c39950001655Guillem, V. M., Tormo, M., Revert, F., Benet, I., García-Conde, J., Crespo, A., & Aliño, S. F. (2002). Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma celllines. The Journal of Gene Medicine, 4(2), 170-182. doi:10.1002/jgm.228Stuchbury, T., Shipton, M., Norris, R., Malthouse, J. P. G., Brocklehurst, K., Herbert, J. A. L., & Suschitzky, H. (1975). A reporter group delivery system with both absolute and selective specificity for thiol groups and an improved fluorescent probe containing the 7-nitrobenzo-2-oxa-1,3-diazole moiety. Biochemical Journal, 151(2), 417-432. doi:10.1042/bj1510417Moret, I., Esteban Peris, J., Guillem, V. M., Benet, M., Revert, F., Dası́, F., … Aliño, S. F. (2001). Stability of PEI–DNA and DOTAP–DNA complexes: effect of alkaline pH, heparin and serum. Journal of Controlled Release, 76(1-2), 169-181. doi:10.1016/s0168-3659(01)00415-1Lisitsyna, E. S., Lygo, O. N., Durandin, N. A., Dement’eva, O. V., Rudoi, V. M., & Kuzmin, V. A. (2012). Superquenching of SYBRGreen dye fluorescence in complex with DNA by gold nanoparticles. High Energy Chemistry, 46(6), 363-367. doi:10.1134/s0018143912060057Venkiteswaran, S., Thomas, T., & Thomas, T. J. (2016). Selectivity of polyethyleneimines on DNA nanoparticle preparation and gene transport. ChemistrySelect, 1(6), 1144-1150. doi:10.1002/slct.201600026Taranejoo, S., Liu, J., Verma, P., & Hourigan, K. (2015). A review of the developments of characteristics of PEI derivatives for gene delivery applications. Journal of Applied Polymer Science, 132(25), n/a-n/a. doi:10.1002/app.42096Del Papa, J., & Parks, R. (2017). Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses, 9(1), 13. doi:10.3390/v9010013Kazemi Oskuee, R., Dabbaghi, M., Gholami, L., Taheri-Bojd, S., Balali-Mood, M., Mousavi, S. H., & Malaekeh-Nikouei, B. (2018). Investigating the influence of polyplex size on toxicity properties of polyethylenimine mediated gene delivery. Life Sciences, 197, 101-108. doi:10.1016/j.lfs.2018.02.008Thomas, T. J., Tajmir-Riahi, H.-A., & Pillai, C. K. S. (2019). Biodegradable Polymers for Gene Delivery. Molecules, 24(20), 3744. doi:10.3390/molecules24203744Miciak, J. J., Hirshberg, J., & Bunz, F. (2018). Seamless assembly of recombinant adenoviral genomes from high-copy plasmids. PLOS ONE, 13(6), e0199563. doi:10.1371/journal.pone.019956